{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-018932","form_type":"8-K","ticker":"MBOT","cik":"0000883975","company_name":"Microbot Medical Inc.","filed_at":"2023-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.594343+00:00","generated_at":"2026-06-14T16:52:32.795913+00:00","sec_items":["1.01","3.02","3.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Microbot Medical closes $2.66M registered direct offering of common stock and warrants at $2.20/share","bullets":["Sold 975,000 shares at $2.20 and 234,500 pre-funded warrants at $2.1999, raising ~$2.66M gross.","Net proceeds to fund LIBERTY Robotic System development, commercialization, regulatory activities, and working capital.","Amended prior warrants: exercise price reduced to $2.20; 1,022,495 Series B warrants extended to Oct 25, 2027.","H.C. Wainwright served as placement agent; received 7% cash fee plus 60,475 warrants at $2.75 exercise price."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-018932","json":"https://secwatch.observer/filing/0001493152-23-018932.json","markdown":"https://secwatch.observer/filing/0001493152-23-018932.md","text":"https://secwatch.observer/filing/0001493152-23-018932.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/883975/000149315223018932/0001493152-23-018932-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/883975/000149315223018932/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T16:52:32.795913+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e9b2794d5cca5d1c70f3cc462d8857e4fe3cd65","claim":"Microbot Medical Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2023-05-16).","evidence_excerpt":"On May 16, 2023 and in connection with the Offering, the Company entered into an engagement letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company pursuant to the Purchase Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/883975/000149315223018932/0001493152-23-018932-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"},{"label":"Effective","value":"2023-05-16"}],"fact_type":"material_agreement"},{"claim_id":"766723a7d95095e0e4692aaeda5c9426c233ff7b","claim":"Microbot Medical Inc. amended Warrant Amendment Agreement with the Investor.","evidence_excerpt":"In connection with the Offering, the Company also entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with the Investor.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/883975/000149315223018932/0001493152-23-018932-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"the Investor"}],"fact_type":"material_agreement"},{"claim_id":"cca7b3c7f0495628ac7157bf66724a26b97bb9c8","claim":"Microbot Medical Inc. entered into Purchase Agreement with an institutional investor valued at approximately $2.66 million (effective 2023-05-23).","evidence_excerpt":"On May 23, 2023, Microbot Medical Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market (the “Offering”), (i) an aggregate of 975,000 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), at an offering price of $2.20 per share and (ii) pre-funded warrants exercisable for up to 234,500 shares of Common Stock (the “Pre-Funded Warrants”) to the Investor at an offering price of $2.1999 per Pre-Funded Warrant, for aggregate gross proceeds from the Offering of approximately $2.66 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/883975/000149315223018932/0001493152-23-018932-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an institutional investor"},{"label":"Value","value":"approximately $2.66 million"},{"label":"Effective","value":"2023-05-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}